文献速递生殖医学

不明原因复发性妊娠丢失中胚胎非整倍体植入前遗传学检测:系统综述与荟萃分析

Preimplantation genetic testing for aneuploidy in unexplained recurrent pregnancy loss: a systematic review and meta-analysis.
PubMed 文献 · Fertil Steril · 2024-08-14

该系统综述与荟萃分析检索PubMed和Cochrane Library至2024年6月,纳入至少2次不明原因复发性妊娠丢失并接受辅助生殖技术(伴或不伴PGT-A)或期待治疗的患者。结果显示PGT-A降低临床妊娠丢失率并提高每移植和每患者活产率,但证据质量低,需要设计良好的随机对照试验。

要点

  • 不明原因复发性妊娠丢失患者胚胎非整倍体率是否更高仍不明确。
  • PGT-A降低临床妊娠丢失率(OR 0.42)并提高每移植活产率(OR 2.17)和每患者活产率(OR 1.85)。
  • 当前证据质量低,需要设计良好的随机对照试验比较ART联合PGT-A与期待治疗。

核心结论

  • 当前低质量证据提示PGT-A提高不明原因复发性妊娠丢失患者每移植和每患者活产率。
  • 需要设计良好的随机对照试验比较ART联合PGT-A与期待治疗用于不明原因复发性妊娠丢失。

研究设计与样本

  • 系统综述与荟萃分析,检索PubMed和Cochrane Library数据库从建库至2024年6月。
  • 纳入至少2次不明原因复发性妊娠丢失并接受辅助生殖技术伴或不伴PGT-A或期待治疗的患者。
  • 主要结局为活产率,次要结局为非整倍体率、临床妊娠率和临床妊娠丢失率。
  • 注册号CRD42021291546。

主要发现

  • 不明原因复发性妊娠丢失夫妇是否具有更高胚胎非整倍体率仍不明确。
  • 整倍体囊胚移植在不明原因复发性妊娠丢失患者与非患者中临床妊娠丢失率(OR 1.10;95%CI 0.57-2.13)和活产率(OR 1.04;95%CI 0.74-1.44)相当。
  • 对妊娠产物进行全面染色体分析显示复发性妊娠丢失患者与非患者非整倍体率相似,不支持子宫内膜选择性较低假说。
  • PGT-A降低不明原因复发性妊娠丢失患者临床妊娠丢失率(OR 0.42;95%CI 0.27-0.67)。
  • PGT-A提高不明原因复发性妊娠丢失患者每移植活产率(OR 2.17;95%CI 1.77-2.65)和每患者活产率(OR 1.85;95%CI 1.18-2.91)。

临床怎么用

  • 当前低质量证据提示PGT-A提高不明原因复发性妊娠丢失患者每移植和每患者活产率。
  • 作者认为需要设计良好的随机对照试验比较ART联合PGT-A与期待治疗用于不明原因复发性妊娠丢失。

局限性

  • 当前证据质量低。
  • 需要设计良好的随机对照试验比较ART联合PGT-A与期待治疗用于不明原因复发性妊娠丢失。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Preimplantation genetic testing for aneuploidy (PGT-A) to deselect aneuploid embryos in assisted reproductive technology (ART) treatment cycles may hold promise by augmenting pregnancy rates per transfer and reducing pregnancy loss rates for patients with unexplained recurrent pregnancy loss (RPL). OBJECTIVE: To explore effectiveness of PGT-A in managing unexplained RPL by evaluating several key aspects: the likelihood of live birth in a subsequent spontaneous pregnancy, whether women with unexplained RPL have a higher rate of aneuploidy, whether euploid blastocysts offer comparable live birth rate (LBR) in patients with unexplained RPL, whether the endometrium is less selective in unexplained RPL loss, and whether PGT-A increases the LBR or reduces pregnancy losses until delivery. DATA SOURCES: PubMed and Cochrane Library databases were searched from inception until June 2024. STUDY SELECTION AND SYNTHESIS: Studies involving patients with ≥2 unexplained RPL who underwent ART with or without PGT-A or expectant management were included. MAIN OUTCOME MEASURES: The primary outcome measure was the LBR. Secondary outcome measures were aneuploidy rate, clinical pregnancy rate, and clinical pregnancy loss rate. RESULTS: Whether couples with unexplained RPL have higher embryo aneuploidy rates remains equivocal. Euploid blastocyst transfers yielded comparable clinical pregnancy loss rate (odds ratio [OR], 1.10; 95% confidence interval [CI], 0.57-2.13) and LBR (OR, 1.04; 95% CI, 0.74-1.44) in patients with and without unexplained RPL. Comprehensive chromosome analysis of products of conception shows similar aneuploidy rates between patients with and without RPL and does not support the less selective endometrium hypothesis. Preimplantation genetic testing for aneuploidy decreased clinical pregnancy loss rate (OR, 0.42; 95% CI, 0.27-0.67) and enhanced LBR per transfer (OR, 2.17; 95% CI, 1.77-2.65) and LBR per patient (OR, 1.85; 95% CI, 1.18-2.91) in patients with unexplained RPL. CONCLUSION AND RELEVANCE: Current low-quality evidence suggests that PGT-A enhances LBR per transfer and per patient in unexplained RPL. Well-designed randomized controlled trials comparing ART with PGT-A vs. expectant management for unexplained RPL are warranted. REGISTRATION NUMBER: CRD42021291546.

来源:Fertil Steril,查看原文。版权归原作者所有。

引用

  1. Mumusoglu S, Telek SB, Ata B, et al. Preimplantation genetic testing for aneuploidy in unexplained recurrent pregnancy loss: a systematic review and meta-analysis. Fertil Steril. 2024. PMID: 39151684. doi:10.1016/j.fertnstert.2024.08.326

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。